Reactogenicity
myalgia, fatigue, pain, headache, tenderness
ADVERSE EVENTS, EVENTS
Solicited local and systemic adverse events were predominantly mild to moderate in severity and self-limited, although more frequent in NVX-CoV2373 recipients and more common after the second injection. After each dose, the most frequently reported solicited local adverse events were injection site pain (NVX-CoV2373: 648 [44.8%] after dose 1 and 850 [61.0%] after dose 2; placebo: 126 [17.4%] after dose 1 and 102 [14.9%] after dose 2) and tenderness (NVX-CoV2373: 817 [56.4%] in dose 1 and 909 [65.2%] in dose 2; placebo: 153 [21.1%] in dose 1 and 97 [14.1%] in dose 2). The median duration of these events was 2 days or less (range, 1–7 days; IQR, 1–3 days) (The most common solicited systemic adverse events were headache (NVX-CoV2373: 440 [30.4%] after dose 1 and 793 [56.9%] after dose 2; placebo: 181 [24.9%] after dose 1 and 119 [17.3%] after dose 2), fatigue (NVX-CoV2373: 350 [24.2%] after dose 1 and 695 [49.9%] after dose 2; placebo: 113 [15.6%] after dose 1 and 100 [14.6%] after dose 2), myalgia (NVX-CoV2373: 492 [34.0%] after dose 1 and 683 [49.0%] after dose 2; placebo: 114 [15.7%] after dose 1 and 82 [12.0%] after dose 2), and malaise (NVX-CoV2373: 215 [14.8%] after dose 1 and 560 [40.2%] after dose 2; placebo: 67 [9.2%] after dose 1 and 51 [7.4%] after dose 2). These adverse events were also detected more frequently among NVX-CoV2373 recipients and after the second injection, with a median duration of 2 days or less (range, 1–7 days; IQR, 1–2 days) (